Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study.

Davide Giuseppe RibaldoneGian Paolo CavigliaRinaldo PellicanoMarta VerneroGiorgio Maria Saracco Mario Morino Marco Astegiano

Published in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (2021)

our results support ABP 501 as an effective and well-tolerated drug, with a good interchangeability with its originator for the treatment of Crohn's disease.

Keyphrases

rheumatoid arthritis
juvenile idiopathic arthritis
combination therapy
systemic lupus erythematosus
ulcerative colitis
disease activity